Complicated Skin and Skin Structure Infections: Prevention and Management Options in an Era of Multidrug-Resistant Organisms
Vance G. Fowler, MD
Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Duke University Medical Center
Durham, North Carolina
Community- and healthcare-associated methicillin-resistant S aureus (MRSA) infections have become a growing public health issue over the past two decades. In this video, Dr. Fowler examines strategies to prevent Staphylococcus aureus infection and transmission, including whole body, systemic, environmental (surface and surroundings) decolonization, as well as pet decolonization in some instances. Interventions for uncomplicated skin and skin structure infections should ideally aim at reducing antibiotic use whenever safe and appropriate. For complicated skin and skin structure infections, there are now several appropriate broad-spectrum antibiotic treatment options available. Dr. Fowler reviews the pros and cons of these agents and provides practical clinical perspectives and advice for successful patient management.
Method of Participation and Evaluation
To participate in this CME activity, please read the following information and click "Launch Program" at the bottom of this page. Complete the online evaluation at the conclusion of the activity. You may print your certificate immediately after completion of the evaluation. Please note: To view this program you need a computer with an Internet browser and audio and video capabilities.
Up to 0.5 AMA PRA Category 1 Credit™
Infectious disease specialists, critical care physicians, hospitalists, surgeons, pharmacists, and other healthcare professionals involved in the management of cSSSIs.
After taking part in this CME activity, learners should be better able to:
- Classify and assess the bacteriology of complicated skin and skin structure infections (cSSSIs)
- Evaluate cSSSIs with consideration of the increasing impact of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA) infection
- Apply evidence-based data and guidelines to the clinical management of cSSSIs, including antibiotic selection, treatment and duration
Vance G. Fowler, MD, has served as a consultant to Arpida Ltd. (Evolva Holding SA), Cubist Pharmaceuticals, Inc., Inhibitex, Inc., Johnson & Johnson, LEO Pharma Inc., Merck & Co., Inc., Shire US Inc., and Targanta Therapeutics Corporation (The Medicines Company); has received honoraria from Arpida Ltd. (Evolva Holding SA), Astellas Pharma US, Inc., Cubist Pharmaceuticals, Inc., Inhibitex, Inc., Merck & Co., Inc., Ortho McNeil, Inc., and Theravance, Inc.; and has received research support from Cerexa, Inc., Cubist Pharmaceuticals, Inc., Inhibitex, Inc., Merck & Co., Inc., and Theravance, Inc.
The Foundation for Improving Patient Outcomes staff and the independent peer reviewer report no financial relationship with commercial interests.
CME Credit Designations
The Foundation for Improving Patient Outcomes (FFIPO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
FFIPO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of the activity.
This activity is eligible for up to 0.5 hour of credit in Category 2-A of the American Osteopathic Association.